195 related articles for article (PubMed ID: 28237660)
21. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
22. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
24. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
[TBL] [Abstract][Full Text] [Related]
25. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
26. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
27. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
28. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
29. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
30. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
32. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.
Hofman P; Ilie M; Hofman V; Roux S; Valent A; Bernheim A; Alifano M; Leroy-Ladurie F; Vaylet F; Rouquette I; Validire P; Beau-Faller M; Lacroix L; Soria JC; Fouret P
Ann Oncol; 2012 Jul; 23(7):1738-43. PubMed ID: 22100693
[TBL] [Abstract][Full Text] [Related]
34. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
Abdelraouf F; Sharp A; Maurya M; Mair D; Wotherspoon A; Leary A; Gonzalez de Castro D; Bhosle J; Nassef A; Gaafar T; Popat S; Yap TA; O'Brien M
BMC Res Notes; 2015 Nov; 8():688. PubMed ID: 26581482
[TBL] [Abstract][Full Text] [Related]
35. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
36. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.
Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S
Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885
[TBL] [Abstract][Full Text] [Related]
37. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
38. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
40. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
